Peloton Therapeutics Inc is categorized under Commercial Biotechnical Research in Dallas, TX and active since 2010.
Peloton Therapeutics Inc was established in 2010, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact John Josey at the company’s single location by writing to 2330 Inwood Road # 226, Dallas, Texas TX 75235 or by phoning (214) 206-8612. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Peloton Therapeutics Inc |
| Contact Person: | John Josey |
| Address: | 2330 Inwood Road # 226, Dallas, Texas 75235 |
| Phone Number: | (214) 206-8612 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Peloton Therapeutics Inc was started in 2010 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact John Josey for inquiries that concern Peloton Therapeutics Inc by calling the company number (214) 206-8612, as your correspondence is most welcome. Additionally, the physical location of the single location of Peloton Therapeutics Inc can be found at the coordinates 32.819042,-96.838795 as well as the street address 2330 Inwood Road # 226 in Dallas, Texas 75235.
For its online presence, you may visit Peloton Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.